89bio Inc (ETNB)
9.46
-0.12
(-1.20%)
USD |
NASDAQ |
May 07, 14:36
89bio Cash from Financing (Quarterly): 162.17M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 162.17M |
| September 30, 2023 | -1.48M |
| June 30, 2023 | 30.77M |
| March 31, 2023 | 321.65M |
| December 31, 2022 | 21.01M |
| September 30, 2022 | 68.63M |
| June 30, 2022 | 28.16M |
| March 31, 2022 | 0.029M |
| December 31, 2021 | 21.89M |
| September 30, 2021 | 0.072M |
| Date | Value |
|---|---|
| June 30, 2021 | 1.692M |
| March 31, 2021 | 0.216M |
| December 31, 2020 | -0.312M |
| September 30, 2020 | 158.29M |
| June 30, 2020 | -0.065M |
| March 31, 2020 | 0.009M |
| December 31, 2019 | 88.38M |
| September 30, 2019 | 0.488M |
| June 30, 2019 | 18.84M |
| March 31, 2019 | 0.00 |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-1.48M
Minimum
Sep 2023
321.65M
Maximum
Mar 2023
48.44M
Average
18.84M
Median
Jun 2019
Cash from Financing (Quarterly) Benchmarks
| Madrigal Pharmaceuticals Inc | 479.92M |
| Akero Therapeutics Inc | 0.502M |
| Viking Therapeutics Inc | 606.04M |
| Galectin Therapeutics Inc | 10.00M |
| Terns Pharmaceuticals Inc | 13.86M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -34.29M |
| Cash from Investing (Quarterly) | -63.64M |
| Free Cash Flow | -129.19M |
| Free Cash Flow Per Share (Quarterly) | -0.4244 |
| Free Cash Flow Yield | -19.20% |